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Evans syndrome (ES) is a rare autoimmune disorder whose long-term outcome is not 
well known. In France, a collaborative pediatric network set up via the National Rare 
Disease Plan now provides comprehensive clinical data in children with this disease. 
Abbreviations: AIHA, autoimmune hemolytic anemia; ALPS, autoimmune lymphoproliferative syndrome; CCR, continuous 
complete remission; CR, complete remission; ES, Evans syndrome; ITP, immune thrombocytopenic purpura; IVIg, intrave-
nous immunoglobulin; NR, no remission; PID, primary genetically identified immunodeficiency; PR, partial remission; SLE, 
systemic lupus erythematosus.
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introduction
The association of immune thrombocytopenic purpura (ITP) 
and autoimmune hemolytic anemia (AIHA), both mediated 
by autoantibodies and responding to splenectomy, was first 
described in 1951 in 24 patients aged 3–78 years by Robert Evans 
(1). Some cases of Evans syndrome (ES) were associated, mainly 
in adults, with various medical conditions such as systemic lupus 
erythematosus (SLE) or malignancies (2). In children, autoim-
mune cytopenia may indicate the presence of an underlying 
primitive immunodeficiency (PID) (3). ES has a chronic and 
relapsing course, and patients are usually dependent on prolonged 
immunosuppressive treatments. Specific effective and non-toxic 
therapies are still elusive (4).
Although the incidence of childhood ITP has been estimated 
at two to five cases per 100,000 per year in children less than 
18  years (5), the precise incidence of childhood AIHA and ES 
has not yet been determined. The literature on pediatric ES is 
composed of isolated case reports and limited retrospective or 
questionnaire-based series (Table 1) (6–9). In the last 30 years, 
less than 100 heterogeneous cases of ES based on a variety of 
definitions have been published, and consistent clinical data 
regarding underlying diseases and long-term follow-up are still 
lacking.
A national network for autoimmune cytopenia in children 
was created in France in 2004, within the scope of a Rare Disease 
Plan further developed in 2007. The network’s working model 
is similar to oncology networks, including referral pediatric 
and adult hematological centers in each region. A retrospective 
pilot study conducted during the 1990–2002 period accreted 
clinical, biological, and treatment data in 36 children with ES 
(10). Since 2004, a formal national prospective observational 
cohort of children with AIHA, chronic ITP, and ES known as 
OBS’CEREVANCE has been set up (11).
The aim of the present collaborative work is to present com-
prehensive long-term follow-up clinical data regarding a large 
national cohort of non-selected children with ES.
Patients and Methods
Patient selection and Data collection
Since 2004, French patients aged less than 18  years presenting 
with autoimmune cytopenia have been consecutively included 
into the national prospective observational OBS’CEREVANCE 
cohort. This study was approved by Bordeaux’s Institutional 
Review Board on Human Research. Written informed consent 
was obtained from the elder patients and/or the subjects’ parents 
and/or the persons with parental authority.
The pediatric hematologists and their referring physicians 
from general hospitals or adult teams prospectively forwarded 
in real time all consultation or hospitalization records for each 
visit to the coordinating center. For each patient, relevant clini-
cal, biological, and treatment data from birth to last follow-up 
were prospectively collected, coded, and integrated by clinical 
Patients aged less than 18 years at the initial presentation of autoimmune cytopenia 
have been prospectively included into a national observational cohort since 2004. 
The definition of ES was restricted to the simultaneous or sequential association of 
autoimmune hemolytic anemia (AIHA) and immune thrombocytopenic purpura (ITP). 
Cases were deemed secondary if associated with a primitive immunodeficiency or 
systemic lupus erythematosus. In December 2014, we analyzed the data pertaining 
to 156 children from 26 centers with ES whose diagnosis was made between 1981 
and 2014. Median age (range) at the onset of cytopenia was 5.4  years (0.2–17.2). 
In 85 sequential cases, the time lapse between the first episodes of AIHA and ITP 
was 2.4 years (0.1–16.3). The follow-up period as from ES diagnosis was 6.5 years 
(0.1–28.8). ES was secondary, revealing another underlying disease, in 10% of cases; 
various associated immune manifestations (mainly lymphoproliferation, other autoim-
mune diseases, and hypogammaglobulinemia) were observed in 60% of cases; and ES 
remained primary in 30% of cases. Five-year ITP and AIHA relapse-free survival were 
25 and 61%, respectively. Overall, 69% of children required one or more second-line 
immune treatments, and 15 patients (10%) died at the age of 14.3 years (1.7–28.1). 
To our knowledge, this is the first consistent long-term clinical description of this rare 
syndrome. It underscores the high rate of associated immune manifestations and the 
burden of long-term complications and treatment toxicity. Future challenges include 
(1) the identification of the underlying genetic defects inducing immune dysregulation 
and (2) the need to better characterize patient subgroups and second-line treatment 
strategies.
Keywords: immune thrombocytopenic purpura, autoimmune hemolytic anemia, child, evans syndrome
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research assistants into the OBS’CEREVANCE Access database 
(Microsoft, Redmond, WA, USA). This database was declared 
to the French commission for information technology and civil 
liberties (CNIL November 9, 2009, 1396823V0). For the present 
study, the database was analyzed on December 31, 2014.
inclusion criteria
Patients with ES defined as the simultaneous (within 1 month) 
or sequential association of ITP and AIHA were included in 
the OBS’CEREVACE cohort. ITP was defined according to 
the international working group criteria, i.e., a platelet count 
<100  G/L on two separate occasions (12). AIHA was defined 
by an Hb level <11 g/dL with a positive direct antiglobulin test 
(DAT) and at least one hemolysis criteria among the following: 
reticulocytosis >120 g/L, free bilirubin >17 μmol/L, and hapto-
globin <10 mg/dL.
exclusion criteria
Patients with isolated DAT and/or compensated hemolysis 
without anemia or patients with antiplatelet antibodies without 
thrombocytopenia were not considered to have ES. Patients with 
inherited red blood cell or platelet diseases, with autoimmune 
cytopenia associated with chemotherapy, bone marrow trans-
plantation, solid organ transplantation, or human immunodefi-
ciency virus, and patients not living in metropolitan France were 
not included in this descriptive study.
Patient Management
The existence of consanguinity or immune manifestations in 
first-degree relatives (father, mother, or siblings) and the complete 
history of included children were recorded, with special attention 
to the initial presentation of AIHA and ITP.
Historically, French pediatric hematology centers have 
adopted common homogeneous practices. Etiological inves-
tigations upon initial diagnosis were consistent with national 
guidelines and were annually repeated during follow-up (http://
www.cerevance.org). Extensive screening for infectious agents 
was conducted and documented. Blood smears were analyzed 
to assess platelet volume, red cell morphology, and presence of 
schistocytes. Complete B- and T-lymphocyte immunophenotyp-
ing was performed in national CEREDIH network laboratories. 
Functional and genetic immune-derived studies to identify 
known genetically identified PIDs were sent mainly to the French 
reference laboratory (CEDI, Dr. C. Picard and Prof. A. Fischer, 
Necker Hospital, Paris). In particular, most children underwent 
screening tests for autoimmune lymphoproliferative syndrome 
TaBle 1 | Main series of es children.
reference Type of study number  
of centers
number  
of patients
Period of  
study years
Median follow-up 
years
number of  
“primarya” es
(7) Retrospective 1 11 18 4.8 7
(9) Prospective 1 10 11 7 2
(6) Retrospective 21 42 24 3 ?
(8) Prospective 1 11 18 8 11
Present study (2015) Prospective 26 156 34 6.8 47
aVarious definitions, follow-up modalities, and durations and data collection.
(ALPS): initial lymphoproliferation, hypergammaglobulinemia, 
or high counts of circulating TCR αβ+ CD4− CD8− double-
negative T lymphocytes (DNTs) led to further investigations 
looking at plasma levels of interleukin (IL)-10 and Fas ligand 
(FasL), functional apoptosis tests, and gene sequencing (13). 
Clinical screening for SLE or other autoimmune diseases was 
conducted at each visit or as required, and usual biological or 
urinary tests were regularly performed.
In this observational real-life study, treatments and supportive 
care were administered according to the CEREVANCE group or 
other published guidelines (14–18). First-line therapies com-
prised mainly intravenous immunoglobulin (IVIg) or steroids 
in ITP and steroids only in AIHA. Second-line therapies, such 
as azathioprine, anti-D, cyclosporine, colchicine, hydroxy-
chloroquine, mycophenolate mofetil, rituximab, splenectomy, 
thrombopoietin-receptor agonists, were given sequentially or in 
combination in the presence of steroid resistance or dependence, 
or in case of relapses.
Definitions
Severity of AIHA and ITP at Initial Diagnosis
A severe clinical condition was defined in ITP as clinical severity 
score ≥3, as defined by the Buchanan’s score [overall bleeding 
severity was graded on a scale of 0 (none) to 5 (life-threatening 
or fatal), mucosal hemorrhages defined a grade of 3 (moderate)] 
(19), and in AIHA as AIHA CEREVANCE score ≥2 (grade 0: 
no sign of anemia; grade 1: pallor, fatigue, no impact on daily 
life; grade 2: tachycardia, malaise, dizziness, significant impact 
on daily life; grade 3: cardiac, renal, or neurological impairment). 
A severe hematological condition was defined in ITP as a platelet 
count <10 g/L and in AIHA as an Hb level <7 g/dL.
Neutropenia
Neutropenia, of presumed immune origin, with or without 
anti-neutrophil autoantibodies, was defined by peripheral neu-
tropenia <1 g/L lasting more than 6 months, provided that an 
infectious or drug-induced cause was excluded.
Primary and Secondary ES
In primary ES cases, no immune manifestations could be identi-
fied during the entire follow-up. Secondary ES cases were associ-
ated with a primary genetically identified immunodeficiency 
(PID) or SLE according to validated criteria (20–22).
ITP and AIHA Outcome
At the last follow-up, the status of each cytopenia was as follows: 
no remission (NR): platelet count <30 g/L or Hb <7 g/dL; partial 
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remission (PR): platelet count 30–100 g/L or Hb 7–11 g/dL with 
reticulocytes >120 g/L; complete remission (CR): platelet count 
>100  g/L and Hb ≥11  g/dL with reticulocytes ≤120  g/L, and 
ongoing treatment or treatment discontinued since less than 
12 months; continuous complete remission (CCR): CR without 
any treatment for at least 12 months. A relapse of ITP or AIHA 
was defined by the recurrence of ITP and/or AIHA after PR or CR.
statistical analysis
All statistical analyses were performed using NCSS 2001 software 
(23). The distribution of qualitative variables between groups was 
compared with the chi-square test or with the Fisher’s exact test. 
ITP and AIHA relapse-free survival (RFS) was estimated using 
the Kaplan–Meier method.
results
Patient characteristics
In December 2014, data from 156 children followed in 26 centers, 
diagnosed between July 1981 and January 2015 were analyzed. 
All families to whom the study was proposed consented to par-
ticipate in the study. Median (range) age at initial cytopenia was 
5.4 years (0.2–17.2). The sex ratio was 1.44 (92/64). There was a 
tendency for male predominance in younger children and female 
predominance in older children (Figure 1).
Eleven of 156 (4%) children were of consanguineous parents 
and 34/156 (22%) had one or more than one first-degree relative 
with immune manifestations, mainly AID, of whom 5 had pre-
sented with autoimmune cytopenia. At birth, 5/94 (5%) children 
were premature (<37 weeks gestational age) and in 9/84 (11%) 
birth weight was <10th percentile for gestational age.
Initial cytopenia was AIHA in 39 patients (25%), ITP in 46 
patients (29%), and simultaneous AIHA and ITP in 71 patients 
(46%). When sequential, the median time lapse between the two 
cytopenias was 2.4 years (0.1–16.3). The clinical presentation was 
severe in 41/102 (40%) ITP patients (five score 4 patients) and in 
65/111 (59%) AIHA patients (17 grade 3 patients). Hematological 
presentation was severe in 69/134 (51%) ITP patients and in 
68/139 (49%) AIHA patients. DAT type was consistently IgG or 
IgG plus complement. An infection was identified upon initial 
diagnosis of ES in 5 simultaneous ITP/AIHA cases (EBV, n = 3; 
FigUre 1 | age and gender distribution at initial diagnosis of the first 
cytopenia in 156 children with es.
one tuberculosis, n = 1; parvovirus, n = 1) and in 13 sequential 
cases (CMV, n = 4; parvoviruses, n = 3; varicella-zoster, n = 2; 
mycoplasma, n = 2; EBV, n = 1; and rotavirus, n = 1).
In 32 children (20%), associated immune neutropenia was 
present, prior to the onset of ES in two patients and during or 
after the diagnosis of ES in 30 patients. Specific autoantibod-
ies were identified in 67% of the 21 patients tested. Clinical 
consequences were mouth ulcers or diarrhea in 33% of cases, 
one or more episodes of severe WHO grade 3–4 bacterial 
sepsis in 43%. Hematopoietic growth factor was required in 
14% of cases.
Diagnosis
Autoimmune lymphoproliferative syndrome–FAS was identified 
in three children upon initial diagnosis of ES (two simultaneous, 
one sequential). They were 4, 11.8, and 13.5 years old at that time 
and had had previous significant lymphoproliferation (supra-
centimetric cervical adenopathies or persistent enlarged spleen 
besides hemolysis). All met the international criteria for ALPS: 
elevated plasma levels of double-negative T cells, FasL, IL-10, 
and defective in vitro Fas-induced lymphocyte apoptosis (20). All 
three had germline mutations in the TNFRSF6 gene.
Thirteen children were diagnosed with SLE. ES occurred at a 
median age of 14 (1–16). Main SLE clinical criteria were achieved 
concomitantly with the onset of ES in 3/13 patients and later 
within a 1- to 10-year period in 10/13 patients. Two patients had 
associated acquired thrombotic thrombocytopenic purpura.
None were diagnosed for malignancy. In 93 children (60%), 
various associated immune clinical or biological manifestations 
were noted, up to 6 years prior to and 15.4 years following ES 
diagnosis. This consisted mainly of significant lymphoprolifera-
tion, other autoimmune diseases, and hypogammaglobulinemia. 
Investigations of PID are being conducted in this subgroup.
Finally, ES was secondary in 10% (n = 16), primary in 30% 
(n = 47), and unclassified in 60% (n = 93) of patients.
Management
Besides first-line therapy with IVIg or steroids, 108 children 
(69%) required a variety of second-line treatments; 74/156 (47%) 
children received more than one second-line treatment (from 
two to seven). ITP was the main treatment target. The median 
time interval between initial diagnoses and the introduction of 
a second-line therapy was longer in sequential forms (1.8 years) 
than in simultaneous forms (0.4 years). This is due to prolonged 
“watch and wait” policy whenever isolated persistent or chronic 
ITP was the initial cytopenia (Figure  2). Secondary ES and 
unclassified cases significantly required second-line treatments 
compared to primary cases (Table 2).
In this observational “real-life” study, the main second-line 
immunosuppressive therapy were rituximab (n =  34), azathio-
prine (n = 16), splenectomy (n = 13), cyclosporine (n = 10), and 
mycophenolate mofetil (n  =  3). In sequential forms, various 
immunosuppressive and other treatments given for the initially 
isolated cytopenia, including splenectomy (n = 7), did not avoid 
the occurrence of the second episode, several months and up to 
16 years later. The rank order of treatments administered in small 
heterogeneous subgroups is under current analyses.
FigUre 2 | Management and outcome of 156 children with es.
September 2015 | Volume 3 | Article 795
Aladjidi et al. Childhood Evans syndrome
Frontiers in Pediatrics | www.frontiersin.org
Outcome
Median follow-up time following ES diagnosis was 6.5  years 
(0.1–28.8). Overall, 15 patients (10%) died at a median age of 
14.3 years (1.7–28.1). Disease-related causes accounted for 30% 
of deaths (four cases of cerebral or gastrointestinal hemorrhages, 
and one severe vasculitis in SLE); in 70% of deaths, all of infectious 
origin, the underlying disease and treatments were suspected to 
have played a role. Median age for the 141 surviving patients at 
last follow-up was 16.1 years (1.6–41.1), and the median delay 
since initiation of the first second-line treatment and last follow-
up was 5 years (0–23.8). At the last follow-up, 115/141 patients 
(74%) were in CCR (n = 41) or CR (n = 64) for both ITP and 
AIHA. In the subgroup of children with a favorable outcome, and 
who had received only first-line therapies, 39/48 children (81%) 
were in CR or CCR at the last follow-up. Finally, 5-year ITP and 
AIHA RFS were 25 and 61%, respectively.
Relapse-free survival analyses were conducted in the first 90 
patients. Since the diagnosis of ES, 74% of the patients (67/90) had 
experienced a relapse, with a median delay of 8 months (41 days 
to 9.5 years). Among those, 52% (35/67) relapsed with ITP and 
AIHA, 40% (27/67) with ITP only, and 8% (5/67) with AIHA only. 
Kaplan–Meier RFS curves for ITP and AIHA are presented in 
Figures 3 and 4.
Discussion
epidemiology
With the help of the French national pediatric network, the 
largest (to our knowledge) prospective observational study 
in children with ES is now available. It describes the clinical 
course of 156 patients reported by 26 regional centers, cov-
ering a 30-year period and spanning 1002 patient-years. 
Approximately 10 new pediatric ES cases are diagnosed per 
year according to our inclusion and exclusion criteria. Obvious 
biases persist due to missing records of milder cases or of PID. 
Some patients registered in the CEREDIH national registry for 
PID who had associated autoimmune bi- or tri-cytopenia were 
not systematically included in the OBS’CEREVANCE database 
(24). This incidence can now be compared to the yearly inci-
dence of 500–800 ITP and 30–50 AIHA cases in our country (5, 
11). Data collected from this prospective long-term follow-up 
confirm our previous observations in 36 and 99 ES patients 
also included in the present cohort (10, 11): a genetic familial 
predisposition in 25% of children, increased initial severity 
in half of the cases, the modest role of infections, a possible 
immune background in 70% of children, and the high impact 
of treatment complications.
FigUre 3 | Kaplan–Meier aiha relapse-free survival in 90 children.
TaBle 2 | Variables associated with the necessity of a second-line 
treatment.
Patients not 
requiring second-
line therapy
Patients requiring 
second-line 
therapy
N = 48 (31%) N = 108 (69%)
Median age at initial cytopenia, 
years (min–max)
5.0 (0.3–17.2) 5.7 (0.2–17.0)
Median age at ES diagnosis, 
years (min–max)
8.9 (0.3–17.2) 8.6 (0.2–19.4)
Sex ratio 0.55 (17/31) 0.77 (47/61)
Prematurity, % (n) 3 (1/32) 6 (4/62)
Consanguinity, % (n) 5 (2/39) 10 (9/87)
First-degree relatives’ immune 
events, % (n)
20 (10/48) 22 (24/108)
Occurrence of ITP and AIHA
 Simultaneous, % (n) 44 (21/48) 46 (50/108)
 Sequential, % (n) 56 (27/48) 54 (58/108)
  –  AIHA as initial  
manifestation, % (n)
27 (13/48) 24 (26/108)
  –  ITP as initial  
manifestation, % (n)
29 (14/48) 30 (32/108)
Associated neutropenia, % (n) 18 (9/48) 21 (23/108)
Primary ES, % (n) 45 (21/47)*§ 55 (26/47)
Secondary ES, % (n) 6 (1/16) 94 (15/16)
Unclassified, % (n) 28 (26/93) 72 (67/93)
*p < 0.05, primary vs. secondary ES.
§p < 0.05, primary vs. others.
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Definitions
Our data should be interpreted taking into account (1) largely 
but not universally accepted definitions, (2) the national com-
mon practice of performing comprehensive phenotypic and 
immune investigations, and (3) long-term evaluation. We have 
retained Evans’s and Pui’s initial definitions of the syndrome: 
hematological ITP and AIHA. Rare cases of combined ITP and/
or AIHA and immune neutropenia registered in our cohort 
need to be included in this ES definition. We did not consider 
isolated positive DAT or antiplatelet antibodies as sufficient for 
ES diagnosis, unless the patients had developed authentic AIHA 
or ITP. In other autoimmune diseases, a strong predictive value 
of isolated antinuclear, antithyroid, or anti-transglutaminase 
antibodies regarding the onset of autoimmune disease has not 
always been demonstrated (25, 26). Whether these patients with 
autoimmune cytopenia and autoantibodies directed against 
other blood cells are at risk of ultimately developing a second 
autoimmune cytopenia still needs to be demonstrated. Since ES 
is characterized by considerable clinical and biological heteroge-
neity regarding its presentation, course and drug responsiveness, 
it should definitely be considered to be a “syndrome.” In a large 
proportion of cases, well-defined diseases such as PID or SLE 
may be diagnosed, even if some of them may not appear until 
several decades later.
Diagnosis
Autoimmune hemolytic anemia and ES differ in children and in 
adults, while ITP shares common characteristics (11). In Michel 
et al.’s adult series including 68 ES patients, no PID was reported, 
and eight cases were associated with hematologic malignant 
conditions (2), while in our pediatric series, 3/156 PIDs were 
identified and no cases of cancer occurred despite significant 
follow-up and an adequate survey. Complete or incomplete SLE 
was diagnosed in 10/68 adult patients as compared to our 13/156 
cases of SLE in young adults who had also developed ES when 
they were teenagers.
In pediatric ES, a well-defined classical etiology is currently 
identified in only 10% of patients at the time of ES diagnosis 
or later (up to 10 years follow-up), and 30% of children did not 
demonstrate other immune manifestation in the long run. In as 
many as 60% of patients, the association with other immuno-
logic diseases suggests that ES occurs within a still-unidentified 
immune background. The number of genetic causes of PID is 
growing, which explains why we anticipate that the percentage of 
secondary ES will increase in the coming years.
Autoimmune cytopenias are recognized as a component of 
emblematic or rarer PID, where many mechanisms of autoim-
munity have been proposed (3, 22, 27). Recent pediatric ES 
series highlighted the importance of ALPS. Autoimmune cyto-
penias occur frequently in this syndrome, e.g., in 47/90 (52%) 
ALPS patients, at any time during the course of the disease, of 
FigUre 4 | Kaplan–Meier iTP relapse-free survival in 90 children.
September 2015 | Volume 3 | Article 797
Aladjidi et al. Childhood Evans syndrome
Frontiers in Pediatrics | www.frontiersin.org
whom 11 had a bi- or tri-cytopenia (28). On the other hand, 
using an “enlarged” ES definition, Teachey et al. reported that 
21/45 (47%) children and adult ES patients showed elevated 
DNTs and defective FAS-mediated apoptosis, and 9/45 had FAS, 
FASL, or CASP10 mutations. The authors claimed that ALPS 
may be more prevalent in childhood ES than previously thought; 
however, this turned out to be questionable due to inclusion 
and definition biases (29, 30). In our series which includes 156 
non-selected ES cases, only three ALPSs were present at initial 
diagnosis, all exhibiting typical ALPS diagnostic criteria. In 
our country, children with PID are registered in the national 
CEREDIH registry according to accurate definitions (24), but 
they are not systematically included in the OBS’CEREVANCE 
database when they have obvious secondary autoimmune cyto-
penia. ES revealing or complicating ALPS or Wiskott–Aldrich 
syndrome may clearly be underrepresented in our cohort. With 
the growing number of recently identified PIDs, and refining 
of key phenotypic descriptions of immune manifestations, 
subgroups of patients will soon be identified and classified 
according to genetic findings.
Primary ES should definitely remain a diagnosis of exclusion 
(1). In the vast majority of ES cases, the combination of multiple 
autoimmune cytopenias may not be a simple coincidence. It is 
of utmost importance to actively and regularly search for an 
underlying abnormal immune disorder, even after the period of 
transition to adulthood.
Outcome
In former series, reported mortality rates for childhood ES were 
7% (3/42) (6), 30% (3/10) (9), and 36% (4/11) (8). Currently, 
the syndrome still has a high 10% mortality rate. In our hands, 
none of the deaths were due to acute anemia, and 27% (4/15) of 
deaths were due to bleeding: this rate in childhood remains much 
greater than in isolated ITP (16, 17). Of note, in an adult series 
including 68 patients, three patients over 60 years of age at the 
time of the diagnosis of AIHA died of cardiovascular complica-
tions, but none of the 16 overall deaths were of hemorrhagic 
origin (2). The hypothesis of autoimmune thrombopathies or 
specific endothelial involvement in pediatric forms can be raised, 
but the evidence is still missing. Besides, 8/15 (53%) of deaths 
were of unclear origin and were possibly related to infections in 
the context of an underlying disease or to intensive treatments. 
They occurred in young adults after a protracted course follow-
ing the onset of ES. This indicates the need to prolong the dura-
tion of management by specialized physicians, and the necessity 
to consider preventive anti-infectious strategies, as well as to 
select immunosuppressive treatments according to an optimal 
benefit–risk ratio.
The challenges to treat ES are known since the initial publica-
tions. However, specific guidelines are still lacking and very few 
treatments have been licensed in children with this syndrome (4, 
31). In all, 69% of our patients required one or several second-
line treatments. Fortunately, 74% were finally in CR or CCR 
upon the last census. ITP is the most severe cytopenia. Expectant 
“watch and wait” strategies are here less recommended than in 
isolated ITP cases because of a specific risk of hemorrhage and 
the increased severity of associated hemolysis. We provide for 
the first time a panorama of the second-line treatment strat-
egy in clinical practice. In addition to rituximab (32–34), we 
underline the benefits of administering classical drugs such as 
azathioprine, cyclosporine, or mycophenolate mofetil, whose 
benefit–risk ratio has rarely been assessed (35). Splenectomy is 
clearly less useful in ES than in isolated chronic ITP and may 
even be dangerous in ALPS (36). Bone marrow transplantation 
should be considered in severe cases with genetically identified 
PID. New collaborative randomized studies are required to 
improve the therapeutic strategies in the different subgroups of 
patients.
conclusion
Even in an apparently primary context, childhood ES should be 
considered as a severe disease requiring specific follow-up until 
adulthood. Pediatric clinicians must be aware that the risk of 
severe hemorrhage is greater than in classical ITP. Most patients 
require several second-line treatments whose burden and associ-
ated complications may be significant. The current challenges 
are to classify 60% of patients in well-defined subgroups and to 
identify the underlying immune genetic deregulations that may 
be helpful to determine therapeutic strategies. Regarding clini-
cal practice, the objectives are to identify markers to predict the 
severity of the disease as well as the benefit–risk ratio of targeted 
treatments.
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